Merrill Lynch Downgrades Universal Health to Hold

By Jason Carr

In a report released today, Kevin Fischbeck from Merrill Lynch downgraded Universal Health (NYSE: UHS) to Hold, with a price target of $135. The company’s shares closed yesterday at $128.06.

According to TipRanks.com, Fischbeck is a 4-star analyst with an average return of 9.1% and a 62.7% success rate. Fischbeck covers the Healthcare sector, focusing on stocks such as Health Insurance Innovations, WellCare Health Plans, and Surgery Partners Inc.

Currently, the analyst consensus on Universal Health is Hold and the average price target is $132.67, representing a 3.6% upside.

In a report released today, Mizuho Securities also downgraded the stock to Hold with a $133 price target.

The company has a one year high of $139.77 and a one year low of $100.82. Currently, Universal Health has an average volume of 780.8K.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. Most recently, in June 2015, Debra Osteen, the SVP of UHS sold 11,305 shares for a total of $1,484,111.

Universal Health Services, Inc. operates as a healthcare management company, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers. It operates through the Acute Care Hospital Services and Behavioral Health Care Services segments. The company was founded by Alan B. Miller in 1978 and is headquartered in King of Prussia, PA.